Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAZEPPA maintenance therapy in metastatic pancreatic adenocarcinoma
2019-004366-18Phase 2Active
- Sponsor
- GERCOR
- Start
- Jan 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Olaparib + durvalumab maintenance with Selumetinib + durvalumab maintenance (2 arms). Primary endpoint: Primary endpoint (Arm A - olaparib-based maintenance efficacy). Started Jan 2020; status: active.
02
Drugs
olaparibselumetinibdurvalumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2019-004366-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004366-18.